Gainers
- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
- InMed Pharmaceuticals Inc. (NASDAQ:INM) gained 70.4% to close at $18.78 after the company on Friday announced a $6 million private placement priced at $8.68 per share.
- Ventyx Biosciences, Inc. (NASDAQ:VTYX) shares surged 65% to close at $38.11 on Monday after Oppenheimer maintained an Outperform rating on the stock and raised its price target from $40 to $65.
- PolyPid Ltd. (NASDAQ:PYPD) gained 58.3% to close at $1.71. The company earlier announced it will present Phase 2 D-PLEX₁₀₀ data at the European Society for Coloproctology Scientific Conference next week.
- Arqit Quantum Inc. (NASDAQ:ARQQ) shares gained 38.1% to close at $7.72. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference later today.
- PaxMedica, Inc. (NASDAQ:PXMD) rose 36.6% to settle at $4.33 after TardiMed Sciences' Michael Derby on Friday disclosed a 63.4% active stake in the company.
- Allego N.V. (NYSE:ALLG) jumped 33.5% to close at $5.90.
- IDEAYA Biosciences, Inc. (NASDAQ:IDYA) jumped 30.7% to close at $12.09. IDEAYA Biosciences disclosed interim Phase 2 clinical results for darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma.
- Clovis Oncology, Inc. (NASDAQ:CLVS) climbed 30.4% to close at $1.50 after the company said Rubraca (Rucaparib) as first-line maintenance treatment improves progression-free survival in women with advanced ovarian cancer across disease risk subgroups.
- Annovis Bio, Inc. (NYSE:ANVS) gained 29.5% to settle at $19.82 on above-average volume.
- Kaspien Holdings Inc. (NASDAQ:KSPN) surged 27.7% to close at $2.86.
- IHS Holding Limited (NYSE:IHS) jumped 24.9% to close at $7.83. IHS Holding, last month, said Q2 EPS results down year-over-year.
- Gogoro Inc. (NASDAQ:GGR) gained 21.3% to close at $5.25. Gogoro recently launched its battery-swapping system and Smart scooters in the Tel Aviv metropolitan area.
- ImmunityBio, Inc. (NASDAQ:IBRX) jumped 20.9% to close at $5.61.
- POINT Biopharma Global Inc. (NASDAQ:PNT) rose 19.8% to close at $10.27 after the company published a poster at ESMO Congress 2022 highlighting updated safety and efficacy data from its Phase 3 SPLASH trial of PNT2002 in metastatic castration-resistant prostate cancer.
- Rackspace Technology, Inc. (NASDAQ:RXT) gained 18.8% to settle at $6.32.
- Magic Empire Global Limited (NASDAQ:MEGL) jumped 17.9% to close at $6.00.
- Regulus Therapeutics Inc. (NASDAQ:RGLS) rose 16.9% to close at $1.94 after the company announced topline safety and PK data from its Phase 1 SAD clinical trial of RGLS8429. The study demonstrated that RGLS8429 has a favorable safety and PK profile.
- TuanChe Limited (NASDAQ:TC) gained 16.8% to close at $3.20.
- Asana, Inc. (NYSE:ASAN) climbed 16.4% to close at $28.71. Asana’s President, CEO and Director Dustin Moskovitz bought a total of 19,273,127 shares at an average price of $18.16.
- Carvana Co. (NYSE:CVNA) gained 15.5% to close at $42.28. Piper Sandler upgraded Carvana from Neutral to Overweight and lowered the price target from $98 to $73.
- Ra Medical Systems, Inc. (NYSE:RMED) surged 15.1% to close at $0.1675 after the company announced a merger agreement with Catheter Precision. Catheter Precision will become a wholly owned subsidiary of Ra Medical.
- Finance Of America Companies Inc. (NYSE:FOA) gained 15.1% to settle at $1.60.
- American Rebel Holdings, Inc. (NASDAQ:AREB) gained 14.7% to close at $0.6650.
- American Rebel’s CEO Andy Ross issued a corporate update in letter to stockholders.
- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) jumped 13.6% to close at $26.46.
- NIO Inc. (NYSE:NIO) surged 13.5% to close at $21.75 following positive analyst coverage from Deutsche Bank and BofA.
- Vinco Ventures, Inc. (NASDAQ:BBIG) rose 13% to close at $1.13.
- SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) gained 12.8% to close at $31.98 after the company announced data from the Phase 3 DeFi trial of nirogacestat in adult patients with desmoid tumors showed nirogacestat treatment resulted in rapid, sustained and statistically significant improvements in primary and all key secondary efficacy endpoints.
- Cardlytics, Inc. (NASDAQ:CDLX) rose 12.2% to close at $14.31.
- Auddia Inc. (NASDAQ:AUUD) gained 12% to settle at $1.40.
- Sigma Lithium Corporation (NASDAQ:SGML) gained 11.4% to close at $27.81.
- Ribbon Communications Inc. (NASDAQ:RBBN) jumped 10.5% to close at $3.57.
- Quhuo Limited (NASDAQ:QH) shares gained 10.2% to close at $3.03 after the company on Friday said it has determined not to proceed with its proposed offering and sale of securities.
- Lucid Group, Inc. (NASDAQ:LCID) jumped 9.7% to close at $16.55 after RF Lafferty initiated coverage on the stock with a Buy rating and a $19 price target.
- NetScout Systems, Inc. (NASDAQ:NTCT) rose 9.4% to close at $33.60. The company, last month, posted upbeat quarterly earnings.
- Reborn Coffee, Inc. (NASDAQ:REBN) rose 8.4% to close at $2.57. Dennis R Egidi recently reported a 9.5% stake in Reborn Coffee.
- Wayfair Inc. (NYSE:W) gained 7.7% to settle at $55.95 amid overall market strength as investors await this week's inflation data.
- Genenta Science S.p.A. (NASDAQ:GNTA) rose 7.5% to close at $5.15.
- Hyperfine, Inc. (NASDAQ:HYPR) gained 7.4% to close at $1.31 after declining 6% on Friday. Hyperfine, last month, reported worse-than-expected Q2 EPS and sales results and issued FY22 sales guidance below estimates.
- Eve Holding, Inc. (NYSE:EVEX) gained 5.7% to close at $8.15. United recently announced a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
- Bristol-Myers Squibb Company (NYSE:BMY) gained 3.1% to settle at $72.36. The FDA approved Bristol Myers Squibb Co's Sotyktu (deucravacitinib), an allosteric tyrosine kinase 2 (TYK2) inhibitor, for moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Atlantic Equities maintained Bristol-Myers Squibb with an Overweight and raised the price target from $83 to $87.
